Clinical trials: Refractory Heart Failure
Heart Failure, Cardiovascular Disease
HeartMate 3™ LIS Study
The purpose of this study is to evaluate a less invasive implantation technique of the HeartMate 3 Left Ventricular Assist System (HM 3 LVAS) in 10 patients.
- Trial name
- HM 3 LIS (NCT02475460)
- Testing
- Less Invasive Surgery (LIS), HeartMate 3™
- Where
- 3 sites in Czechia, Germany
- Volunteers
- 13 people
- Sponsor
- Abbott Medical Devices
Heart Failure, Congestive
Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).
The purpose of this study is to evaluate the safety of KW-3902IV compared to placebo and to determine the diuretic effect of KW-3902IV compared to placebo in patients hospitalized with volume overload due to CHF who are…
- Trial name
- NCT00159627
- Testing
- KW-3902IV
- Where
- 10 sites in United States
- Volunteers
- 52 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Multiple Myeloma
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
To understand the safety and efficacy of Revlimid® 5 mg Capsules (hereinafter referred to as Revlimid) in patients with "relapsed or refractory multiple myeloma" (hereinafter referred to as "relapsed or refractory MM") who have…
- Trial name
- NCT02922543
- Where
- Japan
- Volunteers
- 361 people
- Sponsor
- Celgene
Lymphoma
Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
To understand the safety and efficacy of Revlimid® Capsules 2.5 mg and 5 mg (hereinafter referred to as Revlimid) under actual conditions of use in patients with relapsed or refractory adult T-cell leukemia lymphoma (hereinafter…
- Trial name
- NCT03098589
- Testing
- Revlimid
- Where
- Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
Radiotherapy; Complications, Ventricular Tachycardia
Stereotactic Ablative Radiotherapy for the Treatment of Refractory Ventricular Tachycardia
Ventricular tachycardia (VT) is an abnormal rhythm arising from the bottom chambers (ventricles) of the heart. The hearts of most patients who develop VT have been previously damaged by a myocardial infarction (heart attack) or…
- Conditions
- Radiotherapy; Complications, Ventricular Tachycardia, Structural Heart Abnormality, Heart Failure
- Trial name
- SABRE-VT (NCT05696522)
- Testing
- Stereotactic ablative radiotherapy
- Where
- United Kingdom
- Volunteers
- 4 people
- Sponsor
- Barts & The London NHS Trust
Congestive Heart Failure
Stem Cells Therapy in Advanced Heart Failure
stem cells therapy may be a choice therapy for advanced heart failure patients refractory to medical therapy, internal cardiovertor with a defibrillator (ICD) recipients, and a previous history of myocardial infarction and…
- Trial name
- NCT02871466
- Testing
- stem cells infusion
- Where
- 3 sites in Italy
- Volunteers
- 30 people
- Sponsor
- University of Campania Luigi Vanvitelli
Ischemic Heart Disease
Ozone Therapy in Refractory Ischemic Heart Disease.
The main objective of this clinical trial is to evaluate the effectiveness and cost-effectiveness of adding ozone therapy to standard management of patients with advanced ischemic heart disease refractory to medical and surgical…
- Trial name
- O3Cardio (NCT03660657)
- Testing
- Ozone, Oxygen
- Where
- Spain
- Volunteers
- 1 people
- Sponsor
- Bernardino Clavo, MD, PhD
Advanced Refractory Left Ventricular Heart Failure
MOMENTUM 3 Pivotal Cohort Extended Follow-up PAS
The study will be a prospective, multi-center, non-blinded, controlled study, intended to evaluate the extended use of the HM3 LVAS compared to the HMII LVAS in those patients that are ongoing at the 2-year follow-up in the…
- Trial name
- NCT03982979
- Testing
- HM3 LVAS
- Where
- United States
- Volunteers
- 295 people
- Sponsor
- Abbott Medical Devices
Right Heart Failure
Safety and Feasibility of the CorVad Percutaneous Ventricular Assist System in Refractory Right Heart Failure
The goal of this clinical trial is to evaluate the safety and feasibility of the CorVad Percutaneous Ventricular Assist System (Device model: CorVad RS) in patients with right heart failure who continue to experience hemodynamic…
- Trial name
- NCT07704424
- Testing
- CorVad Percutaneous Ventricular Assist System
- Where
- 2 sites in China
- Volunteers
- 6 people
- Sponsor
- Shenzhen Core Medical Technology CO.,LTD.
Refractory Heart Failure, Chronic Kidney Disease
The Role of Peritoneal Dialysis in Patients With Refractory Heart Failure and Chronic Kidney Disease
In patients with advanced heart failure (HF), systemic congestion is the main indication for hospitalization. Recent evidence has highlighted the role of fluid retention in the pathogenesis of renal dysfunction and subsequent…
- Trial name
- NCT01758627
- Testing
- Peritoneal dialysis (PD)
- Where
- South Korea
- Volunteers
- 7 people
- Sponsor
- Yonsei University
Pleural Effusions, Chronic, Congestive Heart Failure
Tunneled Pleural Catheters for Refractory Effusions Attributed to Congestive Heart Failure (TREAT-CHF) Trial
Congestive heart disease (CHF) can frequently cause transudative pleural effusions, some of which do not completely resolve with diuretics alone.
- Conditions
- Pleural Effusions, Chronic, Congestive Heart Failure, Shortness of Breath
- Trial name
- TREAT-CHF (NCT03696524)
- Testing
- tunneled pleural catheter
- Where
- United States
- Sponsor
- University of California, Los Angeles
Heart Failure
Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure
Cross-over, 2-sequence, 2-treatment, 2-period single-centre, phase IV, randomized, open label study.
- Trial name
- NCT06578520
- Testing
- Dapagliflozin
- Where
- Spain
- Volunteers
- 31 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Heart Failure, Congestive
Randomized Trial for Patients With Chronic Heart Failure With Acute Decompensation
The Company's proprietary products are based on Orqis Medical's hypothesis, supported by early clinical data, that increasing and maintaining continuous blood flow in the descending aorta, known as continuous aortic flow…
- Trial name
- NCT00357591
- Testing
- Continuous Aortic Flow Augmentation
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Orqis Medical Corporation
Advanced Refractory Left Ventricular Heart Failure
MOMENTUM 3 Continued Access Protocol
The objective of the study is to continue to evaluate safety and clinical performance of the HM3 LVAS for the treatment of advanced, refractory, left ventricular heart failure following completion of enrollment in the the…
- Trial name
- MOMENTUM 3 CAP (NCT02892955)
- Testing
- HeartMate 3 LVAS
- Where
- 69 sites in United States
- Volunteers
- 1,685 people
- Sponsor
- Abbott Medical Devices
Cardiovascular Diseases, Heart Diseases
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left…
- Conditions
- Cardiovascular Diseases, Heart Diseases, Heart Failure
- Trial name
- INNOVATE (NCT06310031)
- Testing
- BrioVAD System, HeartMate 3
- Where
- 47 sites in United States
- Volunteers
- 780 people
- Sponsor
- BrioHealth Solutions, Inc.
Ischemic Congestive Cardiomyopathy, Dilated Cardiomyopathy
Optimizing Left Ventricular Lead To Improve Cardiac Output
The purpose of this study is to determine if optimal lead placement, guided by the largest improvement in aortic flow measured by Doppler will: 1. Improve the way the heart's left ventricle functions 2.
- Conditions
- Ischemic Congestive Cardiomyopathy, Dilated Cardiomyopathy, Congestive Heart Failure
- Trial name
- CARE/VOLCANO (NCT01399801)
- Testing
- Doppler flow measurement, standard implantation of the LV lead
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Ann Marie Chikowski
Cardiogenic Shock, Heart Failure
Veno-arterial Extracorporeal Membrane Oxygenation Prior to Left Ventricular Assist Device Implantation.
Cardiogenic shock is an uncommun pathology with a high mortatily rate around 45%. Veno arterial extracorporeal membrane oxygenation (VA-ECMO) is a temporary extracorporeal assist device which restore an adequate blood flow when a…
- Conditions
- Cardiogenic Shock, Heart Failure, Extracorporeal Membrane Oxygenation, Left Ventricular Assist Device
- Trial name
- LVAD-ECMO (NCT03583970)
- Testing
- Left Ventricular Assist Device Implantation
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Central Hospital, Nancy, France
Cirrhosis, Liver, Acute-On-Chronic Liver Failure
Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Refractory Ascites
Point-of-care echocardiography (POC-Echo) is used to determine left ventricular systolic and diastolic dysfunction (LVDD), inferior vena cava (IVC) dynamics and volume status in cirrhosis and Acute-on-chronic liver failure ACLF…
- Conditions
- Cirrhosis, Liver, Acute-On-Chronic Liver Failure, Refractory Ascites, Ascites
- Trial name
- NCT05700708
- Testing
- Echocardiographic assessment
- Where
- India
- Volunteers
- 80 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Heart Decompensation
Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure
Open label study of levosimendan; planned comparison for effectiveness and safety to historic matched case controls from participating sites.
- Trial name
- NCT02973620
- Testing
- Levosimendan
- Sponsor
- Tenax Therapeutics, Inc.
Heart Failure
Cardiac Contractility Modulation (CCM) Therapy in Subjects With Medically Refractory Heart Failure
The study is designed to substantiate the efficacy of Cardiac Contractility Modulation (CCM) in the heart failure population with ejection fraction ranging between 25 and 45%.
- Trial name
- IMPULSE-HF (NCT02857309)
- Testing
- OPTIMIZER, Optimal medical therapy
- Where
- 8 sites in Austria, Germany and 2 more
- Volunteers
- 50 people
- Sponsor
- Impulse Dynamics